- Home
- GNTA vs AFMD Comparison
GNTA vs AFMD Comparison
Compare GNTA & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- AFMD
- Stock Information
- Founded
- GNTA 2014
- AFMD 2000
- Country
- GNTA Italy
- AFMD Germany
- Employees
- GNTA N/A
- AFMD N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- AFMD Health Care
- Exchange
- GNTA Nasdaq
- AFMD Nasdaq
- Market Cap
- GNTA 67.4M
- AFMD 53.3M
- IPO Year
- GNTA 2021
- AFMD 2014
- Fundamental
- Price
- GNTA $5.34
- AFMD $3.36
- Analyst Decision
- GNTA Strong Buy
- AFMD Strong Buy
- Analyst Count
- GNTA 1
- AFMD 5
- Target Price
- GNTA $25.00
- AFMD $16.25
- AVG Volume (30 Days)
- GNTA 28.4K
- AFMD 80.0K
- Earning Date
- GNTA 01-01-0001
- AFMD 11-12-2024
- Dividend Yield
- GNTA N/A
- AFMD N/A
- EPS Growth
- GNTA N/A
- AFMD N/A
- EPS
- GNTA N/A
- AFMD N/A
- Revenue
- GNTA N/A
- AFMD $7,959,927.00
- Revenue This Year
- GNTA N/A
- AFMD N/A
- Revenue Next Year
- GNTA N/A
- AFMD $48.98
- P/E Ratio
- GNTA N/A
- AFMD N/A
- Revenue Growth
- GNTA N/A
- AFMD N/A
- 52 Week Low
- GNTA $2.20
- AFMD $2.92
- 52 Week High
- GNTA $7.28
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- AFMD 44.84
- Support Level
- GNTA $4.89
- AFMD $3.28
- Resistance Level
- GNTA $6.20
- AFMD $3.51
- Average True Range (ATR)
- GNTA 0.70
- AFMD 0.17
- MACD
- GNTA -0.06
- AFMD 0.04
- Stochastic Oscillator
- GNTA 37.32
- AFMD 55.79
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.